Abstract
A persistent, severe reduction of synaptic transmission has been shown to enhance the responsiveness of postsynaptic tissue to the deficient neurotransmitter—a phenomenon called postjunctional supersensitivity1–4. Regardless of whether supersensitivity is induced by removal of presynaptic nerve terminals (denervation) or by chronic postsynaptic receptor blockade, qualitatively similar adaptations in peripheral autonomic targets are usually produced, suggesting that the two types of manipulation are interchangeable and that the postsynaptic molecular alterations they produce are identical2. Following bilateral destruction of dopamine-containing afferents to the nucleus accumbens in the rat, there is a pronounced behavioural hyperresponsiveness to direct dopamine agonists5–7. A remarkably similar situation develops after chronic administration of antipsychotic drugs8–10, such as haloperidol, which are known to be potent antagonists at putative dopamine receptors11–13. We report here that a combination of these two procedures unexpectedly leads to far greater dopaminergic supersensitivity than is observed with either treatment alone. In subjects with the combined treatments, the dopamine agonist apomorphine was more effective in tests of locomotor activation, and additive elevation of the Bmax for 3H-spiperone binding in the nucleus accumbens was observed. These results suggest that denervation and chronic exposure to receptor antagonists can lead to independent processes of postjunctional supersensitivity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Trendelenburg, U. Pharmac. Rev. 18, 629–640 (1966).
Emmelin, N. Pharmac. Rev. 13, 17–37 (1961).
Schwartz, J. C., Costentin, J., Martres, M. P., Protais, P. & Baudry, M. Neuropharmacology 17, 665–685 (1978).
Fleming, W. W. Trends pharmac. Sci. 2, 152–154 (1981).
Costall, B., Hui, S.-C. G. & Naylor, R. J. Neuropharmacology 19, 1039–1048 (1980).
Kelly, P. H., Seviour, P. W. & Iversen, S. R. Brain Res. 94, 507–522 (1975).
Kelly, P. H. & Iversen, S. D. Eur. J. Pharmac. 40, 45–56 (1976).
Jackson, D. M., Anden, N.-E., Engel, J. & Liljequist, S. Psychopharmacology 45, 151–155 (1975).
Gianutsos, G., Hynes, M. D., Drawbaugh, R. & Lal, H. Prog. Neuro-Psychopharmac. 2, 161–167 (1978).
Davis, K. L., Hollister, L. E. & Fritz, W. C. Life Sci. 23, 1543–1548 (1978).
Clement-Cormier, Y. C., Kebabian, J. W., Petzold, G. L. & Greengard, P. Proc. natn. Acad. Sci. U.S.A. 71, 1113–1117 (1974).
Miller, R. J., Horn, A. S. & Iversen, L. L. Molec. Pharmac. 10, 759–766 (1974).
Bockaert, J., Tassin, J. P., Thierry, A. M., Glowinski, J. & Premont, J. Brain Res. 122, 71–86 (1977).
Joyce, E. M. & Koob, G. F. Psychopharmacology 73, 311–313 (1981).
Staunton, D. A., Magistretti, P. J., Schoemaker, W. J. & Bloom, F. E. Brain Res. 232, 391–400 (1982).
Scatchard, G. Ann. N.Y. Acad. Sci. 51, 660–672 (1949).
Rosenfeld, M. R., Seeger, T. F., Sharpless, N. S., Gardner, E. L. & Makman, M. H. Brain Res. 173, 572–576 (1979).
Creese, I., Hamblin, M. W., Leff, S. E. & Sibley, D. R. Handb. Psychopharmac. 16 (in the press).
Guyenet, P. G. et al. Brain Res. 84, 227–244 (1975).
Burt, D. R., Creese, I. & Snyder, S. H. Science 196, 326–328 (1977).
Scatton, B. Eur. J. Pharmac. 46, 363–369 (1977).
Koob, G. F., Stinus, L. & LeMoal, M. Behav. Brain Res. 3, 341–359 (1981).
Staunton, D. A., Magistretti, P. J., Shoemaker, W. J., Deyo, S. N. & Bloom, F. E. Brain Res. 232, 401–412 (1982).
Staunton, D. A., Wolfe, B. B., Groves, P. M. & Molinoff, P. B. Brain Res. 211, 315–327 (1981).
Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. J. biol. Chem. 193, 265–275 (1951).
Bacopoulos, N. G. J. Pharmac. exp. Ther. 219, 708–714 (1981).
Enna, S., Bennett, J., Burt, D., Creese, I. & Snyder, S. H. Nature 263, 338–341 (1976).
Marchais, D., Tassin, J. P. & Bockaert, J. Brain Res. 183, 235–240 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Staunton, D., Magistretti, P., Koob, G. et al. Dopaminergic supersensitivity induced by denervation and chronic receptor blockade is additive. Nature 299, 72–74 (1982). https://doi.org/10.1038/299072a0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/299072a0
This article is cited by
-
Effects of D2 or combined D1/D2 receptor antagonism on the methamphetamine-induced one-trial and multi-trial behavioral sensitization of preweanling rats
Psychopharmacology (2016)
-
Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine
Psychopharmacology (1993)
-
Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system
Cellular and Molecular Neurobiology (1989)
-
Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity II. Theoretical considerations
Journal of Neural Transmission (1985)
-
L-DOPA reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum
Journal of Neural Transmission (1985)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
